|Bid||7.06 x 0|
|Ask||7.08 x 0|
|Day's Range||7.03 - 7.40|
|52 Week Range||3.32 - 9.47|
|Beta (5Y Monthly)||-0.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb. 23, 2022 - Feb. 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.88|
Investors need to pay close attention to BELLUS Health (BLU) stock based on the movements in the options market lately.
Bellus (BLU) delivered earnings and revenue surprises of -20.83% and 0.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
LAVAL, Quebec, November 10, 2021--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders, today reported its financial and operating results for the third quarter ending September 30, 2021.